Jci_page_head_homepage_01 Jci_page_head_homepage_02
Xabier L. Aranguren, Jonathan D. McCue, Benoit Hendrickx, Xiao-Hong Zhu, Fei Du, Eleanor Chen, Beatriz Pelacho, Ivan Peñuelas, Gloria Abizanda, Maialen Uriz, Sarah A. Frommer, Jeffrey J. Ross, Betsy A. Schroeder, Meredith S. Seaborn, Joshua R. Adney, Julianna Hagenbrock, Nathan H. Harris, Yi Zhang, Xiaoliang Zhang, Molly H. Nelson-Holte, Yuehua Jiang, An D. Billiau, Wei Chen, Felipe Prósper, Catherine M. Verfaillie, Aernout Luttun
Published in Volume 118, Issue 2
J Clin Invest. 2008; 118(2):505–514 doi:10.1172/JCI31153
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 3
Early effects of mMAPC-U, mMAPC-VP, and mBMCs in moderate ischemia.

(AD) α-SMA (red) staining at 9 days in adductor of vehicle- (A), mMAPC-U– (B), mBMC– (C), or mMAPC-VP–treated mice (D). Overexposure in the DAPI channel was used to reveal muscle tissue. (E) Left: Laser Doppler measurements in left legs (expressed as % versus the nonligated right leg) before (–) and after (+) ligation of vehicle- (red), mMAPC-U– (black), mBMC- (gray), or mMAPC-VP–treated mice (blue). Right: Swim endurance test measuring hind limb function (expressed as % of baseline [day -1] performance) in vehicle- (red), mMAPC-U– (black), mBMC- (gray), or mMAPC-VP–injected mice (blue). The dotted line indicates the performance level of mice in which only one femoral artery was ligated 9 days prior and that were untreated. (FH) Magnetic resonance spectra (MRS) recorded at 9 days to determine the energetic status (expressed as Σ[PCr/Pi, PCr/γ-ATP], with 23 as normal reference value) in the lower limb muscle showing representative overlays of the spectrum of a nonischemic mouse (gray in FH) and those of vehicle- (red; F), mMAPC-U– (blue; G), and mBMC- or mMAPC-VP-injected mice (green; H). *P < 0.05 versus vehicle for each corresponding time point. Scale bars: 100 μm.